Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

Beth Apsel, Jimmy A. Blair(University of California, Berkeley), Beatriz González(MRC Laboratory of Molecular Biology), Tamim Nazif(Howard Hughes Medical Institute), Morri E. Feldman(University of California, San Francisco), Brian Aizenstein, Randy Hoffman, Roger Williams(MRC Laboratory of Molecular Biology), Kevan M. Shokat(Howard Hughes Medical Institute), Zachary A. Knight(Howard Hughes Medical Institute)
Nature Chemical Biology
October 12, 2008
10.1038/nchembio.117
Cited by 438Open Access
Full Text

Abstract

Related Papers

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al.|Science|2007|4.5k
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
M. Gorre, Mansoor Mohammed, Katharine Ellwood et al.|Science|2001|3.1k
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
David T. Dudley, Long Pang, Stuart J. Decker et al.|Proceedings of the National Academy of Sciences|1995|2.7k
Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation
Oliver Borst, Britta Walker, Patrick Münzer et al.|Cellular Physiology and Biochemistry|2013|1.9k
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
Markus Guba, Philipp von Breitenbuch, Markus Steinbauer et al.|Nature Medicine|2002|1.7k